Taste disturbance by angiotensin-converting enzyme inhibitors/angiotensin-2 receptor blockers To the Editor: We read with interest the recent article by Kusaba et al. 1 The authors found that both recognition and detection thresholds were increased in patients with chronic kidney disease (CKD). They also found that patients with diabetic nephropathy had a higher detection threshold than non-diabetic patients with CKD. In this regard, one has to consider the taste disturbance caused by angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin-2 receptor blockers (ARBs). 2, 3 The authors reported that ACEIs and/or ARBs were prescribed for 72% of the patients with CKD. This could explain the higher taste thresholds in CKD. Similarly, it should be noted that ACEIs and/or ARBs are more likely to be prescribed for patients with diabetic nephropathy than for patients without diabetes mellitus. Although the authors stated no difference in taste thresholds based on the administration of antihypertensives except for diuretics, the numbers obtained by comparison (22 versus 7) do not yield enough statistical power. Therefore, we are concerned about the effects of ACEIs and/or ARBs mentioned in the study.
It is of interest that the recognition threshold for salty taste was recovered after 1 week of sodium restriction. This recovery may be unrelated to ACEI and/or ARB use. The authors should clarify whether there was a change in ACEI and/or ARB use during the 1 week of sodium restriction. That there was no significant difference in discrimination threshold between before and after the sodium restriction may be due to ACEI and/or ARB use. Further studies without ACEI and ARB use are therefore warranted.
The Authors Reply: We appreciate the interest of Drs Ebihara and Kohzuki 1 regarding our paper. 2 We present here our reply per their request.
First, regarding the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-2 receptor blockers (ARBs) on taste disturbance, these drugs were administered to 21 patients (72%) in our study. We further analyzed the effects of these drugs, which revealed that the recognition threshold for salty taste was 0.91±0.31% for patients who were administered these drugs and 0.80±0.11% for those who were not. The detection thresholds were 0.77±0.24% and 0.68±0.10%, respectively. Both thresholds were higher in patients administered ACEI or ARB; however, these differences were not statistically significant. Because we did not mainly focus on the effects of the administered drugs on gustatory threshold in this study, we cannot exclude the possibility that the small sample size might have led to an inadequate assessment as described in the limitations. Second, Ebihara and Kohzuki pointed out the possibility that the change of administered drugs during the study period might have affected the improvement in gustatory threshold. However, the administered drugs were not changed during the study period, indicating that sodium restriction, even for 1 week, definitely improves the gustatory threshold.
Unfortunately, it is still unclear whether the high prevalence of ARB or ACEI use in chronic kidney disease (CKD) patients overcomes the impact of other factors (e.g., uremic status, abnormal zinc metabolism, excessive sodium intake, and administered drugs). Knowledge about taste disturbance in CKD is limited, and hence further investigations into this topic are required.
